Folic Acid-Containing Dietary Supplement Consumption and Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients: NHANES 1999–2014
The risk of cardiovascular mortality among patients with rheumatoid arthritis (RA) is double than that of the general population.1 Elevated homocysteine level is considered to be one of the possible factors for increased cardiovascular mortality in RA patients.2 Homocysteine elevation is prevalent among RA patients,3 and a persistent increase in homocysteine level has been reported in patients treated with disease-modifying antirheumatic drugs (DMARDs).4 Folic acid (FA) supplementation can lower blood homocysteine levels by 25%5 and reduce the risk of cardiovascular diseases (CVDs) in the general population by nearly 4%.6 Benefits of long-term FA supplementation, if any, in RA patients are not known. The present study examines the association between consumption of FA-containing dietary supplement and the risk of CVDs in RA patients treated with DMARDs.
We used data form the National Health and Nutrition Examination Survey (NHANES) 1999–2014, a complex, stratified,...
KEY WORDSarthritis cardiovascular diseases prevention
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they do not have a conflict of interest.
- 5.Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists’ Collaboration. BMJ. 1998;316:894–898.Google Scholar
- 6.Li Y, Huang T, Zheng Y, et al. Folic acid supplementation and the risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2016;5.Google Scholar
- 7.CDC National Center for Health Statistics. National Health and Nutrition Examination Survey. 2011. http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm. Accessed 29 Nov 2016.